Correlation Between CytomX Therapeutics and Rhythm Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both CytomX Therapeutics and Rhythm Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CytomX Therapeutics and Rhythm Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between CytomX Therapeutics and Rhythm Pharmaceuticals, you can compare the effects of market volatilities on CytomX Therapeutics and Rhythm Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CytomX Therapeutics with a short position of Rhythm Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of CytomX Therapeutics and Rhythm Pharmaceuticals.

Diversification Opportunities for CytomX Therapeutics and Rhythm Pharmaceuticals

-0.38
  Correlation Coefficient

Very good diversification

The 3 months correlation between CytomX and Rhythm is -0.38. Overlapping area represents the amount of risk that can be diversified away by holding CytomX Therapeutics and Rhythm Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Rhythm Pharmaceuticals and CytomX Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CytomX Therapeutics are associated (or correlated) with Rhythm Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Rhythm Pharmaceuticals has no effect on the direction of CytomX Therapeutics i.e., CytomX Therapeutics and Rhythm Pharmaceuticals go up and down completely randomly.

Pair Corralation between CytomX Therapeutics and Rhythm Pharmaceuticals

Given the investment horizon of 90 days CytomX Therapeutics is expected to under-perform the Rhythm Pharmaceuticals. In addition to that, CytomX Therapeutics is 1.01 times more volatile than Rhythm Pharmaceuticals. It trades about -0.01 of its total potential returns per unit of risk. Rhythm Pharmaceuticals is currently generating about 0.2 per unit of volatility. If you would invest  4,597  in Rhythm Pharmaceuticals on August 13, 2024 and sell it today you would earn a total of  2,136  from holding Rhythm Pharmaceuticals or generate 46.47% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

CytomX Therapeutics  vs.  Rhythm Pharmaceuticals

 Performance 
       Timeline  
CytomX Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days CytomX Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong primary indicators, CytomX Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.
Rhythm Pharmaceuticals 

Risk-Adjusted Performance

15 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Rhythm Pharmaceuticals are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady basic indicators, Rhythm Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

CytomX Therapeutics and Rhythm Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with CytomX Therapeutics and Rhythm Pharmaceuticals

The main advantage of trading using opposite CytomX Therapeutics and Rhythm Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CytomX Therapeutics position performs unexpectedly, Rhythm Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rhythm Pharmaceuticals will offset losses from the drop in Rhythm Pharmaceuticals' long position.
The idea behind CytomX Therapeutics and Rhythm Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments